UNIMED stock faces weaker exports as H1 profit falls 15.2%
Published on 11/09/2026 at 02:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch
- UNIMED's revenue declined as export sales weakened after a major customer did not renew orders.
- Operating income and operating cash flow improved despite pressure on the bottom line.
- Tax-related charges and inventory write-downs reduced first-half earnings.
UNIMED reported a 15.2% decline in net profit for the six months ended June 30, 2026, as weaker exports and exceptional charges outweighed stronger operating income. African Manager reported the results on October 27.
Exports weaken first-half revenue
Revenue fell 10.8% year on year to TND 64.5 million from TND 72.3 million. Export sales dropped 39% to TND 13.2 million after a major subcontracting customer did not renew its orders. Domestic sales increased 1.3% to TND 51.2 million, partly offsetting the export decline.
Exceptional charges cut earnings
Net profit fell to TND 8.8 million from TND 10.4 million, while earnings per share declined to TND 0.276 from TND 0.325. Other ordinary losses rose to TND 6.5 million from TND 0.1 million, including TND 4.4 million related to a tax-audit settlement and TND 1.8 million from inventory write-downs.
Operating income nevertheless increased 15.6% to TND 20.6 million from TND 17.8 million, helped by lower depreciation and provisions. Operating cash flow rose to TND 15.1 million from TND 3.9 million, while UNIMED repaid TND 27.7 million in borrowings and took on TND 16.7 million in new loans.
Business model and competition
UNIMED develops and manufactures sterile pharmaceutical products, including injectables, eye drops and infusion solutions, for Tunisia and export markets. Its product range also includes powder injectables and ophthalmic and ear-care products, according to the UNIMED company website. Germany Trade & Invest identifies Medis, Saiph and Teriak as competing Tunisian pharmaceutical manufacturers alongside UNIMED. The company is one of several established local producers in a market where domestic manufacturers cover much of local demand and also serve international customers.
Tunisian pharmaceutical companies operate in a market shaped by local production, export opportunities and payment risks, according to Germany Trade & Invest. For UNIMED, the first-half figures leave export recovery and the effect of exceptional charges as key factors for the next reporting periods.
UNIMED at a glance
- Company: Unite de Fabrication de Medicaments
- ISIN: TN0007720014
- Ticker: UMED
- Listing: BVMT
- Country: Tunisia
- Business scope: Pharmaceuticals
Current market reports are available in the market overview.
More news and analyses on UNIMED stock.
